Device Trial Radar · NCT07920055
Sirolimus-Coated Versus Paclitaxel-Coated Balloon for Recurrent Coronary In-Stent Restenosis After Prior Paclitaxel-Coated Balloon Treatment (SPRIT)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
106
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
Aug 31, 2028
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Sir Run Run Shaw HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, multicenter, randomized, open-label, noninferiority trial will compare a sirolimus-coated balloon (SeQuent SCB) with a paclitaxel-coated balloon (RESTORE DEB) in 106 adults with recurrent coronary in-stent restenosis after prior paclitaxel-coated balloon treatment of the same segment. Participants will be randomized 1:1 to treatment of the target lesion with one of the study devices. The primary outcome is in-segment late lumen loss on quantitative coronary angiography 9 months after the index procedure. Clinical follow-up is scheduled at 30 days and 6, 9, and 12 months. Angiographic analysis and clinical event adjudication will be performed blinded to treatment assignment.
Conditions
- Coronary In-stent Restenosis
- Coronary Artery Disease
Interventions
SeQuent SCB sirolimus-coated balloonDevice
Coronary balloon angioplasty of eligible target lesions
RESTORE DEB paclitaxel-coated balloonDrug
Coronary balloon angioplasty of eligible target lesions
Primary outcomes
What the sponsor says the trial is designed to measure.
- In-Segment Late Lumen Loss at 9 MonthsTime frame: Immediately after index procedure and at 9 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sir Run Run Shaw Hospital
Hangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.